Skip to main content
Premium Trial:

Request an Annual Quote

Natera Partners With One Lambda to Distribute Kidney Transplant Rejection Test

NEW YORK (GenomeWeb) – Natera said today that it has struck a distribution deal with Thermo Fisher Scientific's One Lamda to co-distribute its cell-free DNA-based kidney transplant rejection test in the US.

Parisa Khosropour, president of transplant diagnostics at Thermo Fisher Scientific, said in a statement that Natera's cfDNA test "complements [its] existing transplant offerings and enables us to provide a more advanced portfolio for monitoring kidney rejection."

Natera CEO Steve Chapman said that the firm would still have its own direct sales team when it launches its test this year, but would also be able to leverage One Lambda's commercial infrastructure.

The company published a validation study of its kidney transplant rejection assay in the Journal of Clinical Medicine last December, retrospectively analyzing 300 plasma samples from 193 patients. Last month, Natera said that it had submitted a dossier to the Centers for Medicare and Medicaid Services for reimbursement and anticipated that its test would be priced at a similar rate to CareDx's cfDNA assay for kidney transplant rejection of $2,800.

The Scan

Positive Framing of Genetic Studies Can Spark Mistrust Among Underrepresented Groups

Researchers in Human Genetics and Genomics Advances report that how researchers describe genomic studies may alienate potential participants.

Small Study of Gene Editing to Treat Sickle Cell Disease

In a Novartis-sponsored study in the New England Journal of Medicine, researchers found that a CRISPR-Cas9-based treatment targeting promoters of genes encoding fetal hemoglobin could reduce disease symptoms.

Gut Microbiome Changes Appear in Infants Before They Develop Eczema, Study Finds

Researchers report in mSystems that infants experienced an enrichment in Clostridium sensu stricto 1 and Finegoldia and a depletion of Bacteroides before developing eczema.

Acute Myeloid Leukemia Treatment Specificity Enhanced With Stem Cell Editing

A study in Nature suggests epitope editing in donor stem cells prior to bone marrow transplants can stave off toxicity when targeting acute myeloid leukemia with immunotherapy.